From Dr Paul Walker ( Spectral's CEO )
Dr Paul Walker said, in his Rodman & Renshaw conference in New York, that the mortality of screened but not randomized patients with EAA>0.6 and MODS>9 is 62% and composite mortality of all randomized patients (176) is 45%.-------------------------------------------------------Then, if we have the same rate in the trial, it's meant 62% for placebo and 28% for PMX and 34% absolute.---------------------------------------------------But to be conservative and prudent, we can think about 55%-35% for 20% absolute and sure FDA approval in this case. Read more at https://www.stockhouse.com/companies/bullboard#SARtoVElihmdldwe.99